These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 30872517)

  • 1. Ushering in the next generation of precision trials for pediatric cancer.
    DuBois SG; Corson LB; Stegmaier K; Janeway KA
    Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Medicine in Pediatric Oncology.
    Vo KT; Parsons DW; Seibel NL
    Surg Oncol Clin N Am; 2020 Jan; 29(1):63-72. PubMed ID: 31757314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
    Adashek JJ; Subbiah V; Kurzrock R
    Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps.
    Printz C
    Cancer; 2020 Jan; 126(2):239-240. PubMed ID: 31917472
    [No Abstract]   [Full Text] [Related]  

  • 8. Advancing cancer drug development through precision medicine and innovative designs.
    Zhang W; Wang J; Menon S
    J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision oncology: A new era of cancer clinical trials.
    Renfro LA; An MW; Mandrekar SJ
    Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to therapeutic drug development for childhood cancers.
    Campbell K; Ma C; DuBois SG
    Curr Opin Pediatr; 2020 Feb; 32(1):35-40. PubMed ID: 31790026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials in the era of personalized oncology.
    Maitland ML; Schilsky RL
    CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving paradigms for new agent development in pediatric oncology.
    Flynn A; Fox E
    Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
    Tao JJ; Schram AM; Hyman DM
    Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing precision cancer medicine in the genomic era.
    Chen HZ; Bonneville R; Roychowdhury S
    Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definitions and statistical properties of master protocols for personalized medicine in oncology.
    Renfro LA; Mandrekar SJ
    J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting.
    Hafez N; Rugo HS; Tempero MA; Fox E; Reaman GH; Lyerly HK; Walker D; LoRusso PM
    Clin Cancer Res; 2020 Sep; 26(18):4743-4747. PubMed ID: 32571790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward a More Precise Future for Oncology.
    Murciano-Goroff YR; Taylor BS; Hyman DM; Schram AM
    Cancer Cell; 2020 Apr; 37(4):431-442. PubMed ID: 32289268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.